TAMIFLU®
(oseltamivir phosphate)
CAPSULES AND FOR ORAL SUSPENSION
Rx only

TAMIFLU attacks the influenza virus and stops it from spreading inside your body. TAMIFLU treatsflu at its source by attacking the virus that causes the flu rather than simply masking symptoms.

DESCRIPTION
TAMIFLU (oseltamivir phosphate) is available as a capsule containing 75 mg oseltamivir for oral use in the form of oseltamivir phosphate and as a powder for oral suspension which when constituted with water as directed contains 12 mg/mL oseltamivir base. In addition to the active ingredient each capsule contains pregelatinized starch talc povidone K 30 croscarmellose sodium and sodium stearyl fumarate. The capsule shell contains gelatin titanium dioxide yellow iron oxide black iron oxide and red iron oxide. Each capsule is printed with blue ink which includes FD&C Blue No. 2 as the colorant. In addition to the active ingredient the powder for oral suspension contains xanthan gum monosodium citrate sodium benzoate sorbitol saccharin sodium titanium dioxide and tutti-frutti flavoring. Oseltamivir phosphate is a white crystalline solid with the chemical name (3R4R5S)-4-acetylamino- 5-amino-3(1-ethylpropoxy)-1-cyclohexene-1-carboxylic acid ethyl ester phosphate (1:1). The chemical formula is C16H28N2O4 (free base). The molecular weight is 312.4 for oseltamivir free base and 410.4 for oseltamivir phosphate salt. The structural formula is as follows:

MICROBIOLOGYMechanism of ActionOseltamivir is an ethyl ester prodrug requiring ester hydrolysis for conversion to the active form oseltamivir carboxylate. The proposed mechanism of action of oseltamivir is inhibition of influenza virus neuraminidase with the possibility of alteration of virus particle aggregation and release.

Antiviral Activity In VitroThe antiviral activity of oseltamivir carboxylate against laboratory strains and clinical isolates of influenza virus was determined in cell culture assays. The concentrations of oseltamivir carboxylate required for inhibition of influenza virus were highly variable depending on the assay method used and the virus tested. The 50% and 90% inhibitory concentrations (IC50 and IC90) were in the range of 0.0008 µM to >35 µM and 0.004 µM to >100 µM respectively (1 µM=0.284 µg/mL). The relationship between the in vitro antiviral activity in cell culture and the inhibition of influenza virus replication in humans has not been established.

ResistanceInfluenza A virus isolates with reduced susceptibility to oseltamivir carboxylate have been recovered in vitro by passage of virus in the presence of increasing concentrations of oseltamivir carboxylate. Genetic analysis of these isolates showed that reduced susceptibility to oseltamivir carboxylate is associated with mutations that result in amino acid changes in the viral neuraminidase or viral hemagglutinin or both. Resistance mutations selected in vitro in neuraminidase are I222T and H274Y in influenza A N1 and I222T and R292K in influenza A N2. Mutations E119V R292K and R305Q have been selected in avian influenza A neuraminidase N9. Mutations A28T and R124M have been selected in the hemagglutinin of influenza A H3N2 and mutation H154Q in the hemagglutinin of a reassortant human/avian virus H1N9.
In clinical studies in the treatment of naturally acquired infection with influenza virus 1.3% (4/301) of posttreatment isolates in adult patients and adolescents and 8.6% (9/105) in pediatric patients age 1 to 12 years showed emergence of influenza variants with decreased neuraminidase susceptibility in vitro to oseltamivir carboxylate. Mutations in influenza A resulting in decreased susceptibility were H274Y in neuraminidase N1 and E119V and R292K in neuraminidase N2. Insufficient information is available to fully characterize the risk of emergence of TAMIFLU resistance in clinical use. In clinical studies of postexposure and seasonal prophylaxis determination of resistance was limited by the low overall incidence rate of influenza infection and prophylactic effect of TAMIFLU.

Cross-resistanceCross-resistance between zanamivir-resistant influenza mutants and oseltamivir-resistant influenza mutants has been observed in vitro. Due to limitations in the assays available to detect drug-induced shifts in virus susceptibility an estimate of the incidence of oseltamivir resistance and possible crossresisance to zanamivir in clinical isolates cannot be made. However two of the three oseltamivirinduced mutations (E119V H274Y and R292K) in the viral neuraminidase from clinical isolates occur at the same amino acid residues as two of the three mutations (E119G/A/D R152K and R292K) observed in zanamivir-resistant virus.

Immune ResponseNo influenza vaccine interaction study has been conducted. In studies of naturally acquired and experimental influenza treatment with TAMIFLU did not impair normal humoral antibody response to infection.

CLINICAL PHARMACOLOGYPharmacokineticsAbsorption and BioavailabilityOseltamivir is readily absorbed from the gastrointestinal tract after oral administration of oseltamivir phosphate and is extensively converted predominantly by hepatic esterases to oseltamivir carboxylate. At least 75% of an oral dose reaches the systemic circulation as oseltamivir carboxylate. Exposure to oseltamivir is less than 5% of the total exposure after oral dosing (see table 1).

table 1 Mean (% CV) Pharmacokinetic Parameters of Oseltamivir andOseltamivir Carboxylate After a Multiple 75 mg Capsule Twice Daily OralDose (n=20)

Parameter	Oseltamivir	Oseltamivir Carboxylate
Cmax (ng/mL)	65.2 (26)	348 (18)
AUC0-12h (ng·h/mL)	112 (25)	2719 (20)

Plasma concentrations of oseltamivir carboxylate are proportional to doses up to 500 mg given twicedaily (see DOSAGE AND ADMINISTRATION).
Coadministration with food has no significant effect on the peak plasma concentration (551 ng/mLunder fasted conditions and 441 ng/mL under fed conditions) and the area under the plasmaconcentration time curve (6218 ng·h/mL under fasted conditions and 6069 ng·h/mL under fedconditions) of oseltamivir carboxylate.

DistributionThe volume of distribution (Vss) of oseltamivir carboxylate following intravenous administration in 24subjects ranged between 23 and 26 liters.
The binding of oseltamivir carboxylate to human plasma protein is low (3%). The binding ofoseltamivir to human plasma protein is 42% which is insufficient to cause significant displacementbaseddrug interactions.

MetabolismOseltamivir is extensively converted to oseltamivir carboxylate by esterases located predominantly inthe liver. Neither oseltamivir nor oseltamivir carboxylate is a substrate for or inhibitor of cytochromeP450 isoforms.

EliminationAbsorbed oseltamivir is primarily (>90%) eliminated by conversion to oseltamivir carboxylate. Plasmaconcentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oraladministration. Oseltamivir carboxylate is not further metabolized and is eliminated in the urine.Plasma concentrations of oseltamivir carboxylate declined with a half-life of 6 to 10 hours in mostsubjects after oral administration. Oseltamivir carboxylate is eliminated entirely (>99%) by renalexcretion. Renal clearance (18.8 L/h) exceeds glomerular filtration rate (7.5 L/h) indicating that tubularsecretion occurs in addition to glomerular filtration. Less than 20% of an oral radiolabeled dose iseliminated in feces.

Prescription items are NON-RETURNABLE and NON-REFUNDABLE.

Code: 012RL01-75X10
Product: Tamiflu Rx Caps 75 mg x 10 pack
Price: $142.35